|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Insider Trading - Kiniksa Pharmaceuticals Ltd. (KNSA)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch What is insider trading>> |
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2018-05-29 Purchase |
2018-05-31 4:19 pm |
Kiniksa Pharmaceuticals Ltd. | KNSA | Flynn James E Deerfield Mgmt L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Special Situations Fund L.P. DEERFIELD PARTNERS L.P. 10% Owner |
843,352 | $18.97 | $15,996,834 | 843,352 (Indirect) |
View |
| 2018-05-29 Purchase |
2018-05-31 4:13 pm |
Kiniksa Pharmaceuticals Ltd. | KNSA | Cormorant Asset Management LP Chen Bihua Cormorant Global Healthcare GP LLC Cormorant Global Healthcare Master Fund LP 10% Owner |
69,444 | $18 | $1,249,992 | 900,443 (Indirect Direct) |
View |
| 2018-02-09 Purchase |
2018-05-31 4:10 pm |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
3,000,000 | $18 | $54,000,000 | 14,658,102 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2019-06-06 Other |
2019-06-07 6:30 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
200,423 | $0 | 2,700,597 (Indirect) |
View |
| 2019-06-06 Other |
2019-06-07 6:30 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
14,840 | $0 | 2,700,597 (Direct) |
View |
| 2019-06-06 Other |
2019-06-07 6:30 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
14,840 | $0 | 2,700,597 (Direct) |
View |
| 2019-05-29 Option Award |
2019-05-31 4:01 pm |
N/A 2029-05-29 |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
37,520 | $15.47 | 37,520 (Indirect) |
View |
| 2019-05-29 Option Award |
2019-05-31 4:01 pm |
N/A 2029-05-29 |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
37,520 | $15.47 | 37,520 (Indirect) |
View |
| 2019-05-29 Option Award |
2019-05-30 6:33 pm |
N/A 2029-05-28 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Quart Barry D Director |
18,760 | $15.47 | 18,760 (Direct) |
View |
| 2019-05-29 Option Award |
2019-05-30 6:33 pm |
N/A 2029-05-28 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Malley Thomas Director |
18,760 | $15.47 | 18,760 (Direct) |
View |
| 2019-05-29 Option Award |
2019-05-30 6:32 pm |
N/A 2029-05-28 |
Kiniksa Pharmaceuticals Ltd. | KNSA | McCain Tracey L Director |
18,760 | $15.47 | 18,760 (Direct) |
View |
| 2019-05-29 Option Award |
2019-05-30 6:32 pm |
N/A 2029-05-28 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Popovits Kimberly J Director |
18,760 | $15.47 | 18,760 (Direct) |
View |
| 2019-03-04 Option Award |
2019-03-06 6:30 pm |
N/A 2029-03-03 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Heberlig Chris CFO |
46,000 | $17.92 | 46,000 (Direct) |
View |
| 2019-03-04 Option Award |
2019-03-06 6:30 pm |
N/A 2029-03-03 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Mahoney Stephen F. COO |
83,000 | $17.92 | 83,000 (Direct) |
View |
| 2019-03-04 Option Award |
2019-03-06 6:29 pm |
N/A 2029-03-03 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Paolini John F. SVP & Chief Medical Officer |
51,000 | $17.92 | 51,000 (Direct) |
View |
| 2019-03-04 Option Award |
2019-03-06 6:29 pm |
N/A 2029-03-03 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Patel Sanj K CEO, Chairman |
187,000 | $17.92 | 187,000 (Direct) |
View |
| 2019-03-04 Option Award |
2019-03-06 6:28 pm |
N/A 2029-03-03 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Beetham Thomas W. EVP & Chief Legal Officer |
42,000 | $17.92 | 42,000 (Direct) |
View |
| 2019-03-04 Option Award |
2019-03-06 6:27 pm |
N/A 2029-03-03 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Levy Richard S Director |
37,965 | $17.92 | 37,965 (Direct) |
View |
| 2019-02-04 Option Award |
2019-02-06 5:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
181,525 | $0 | 8,837,349 (Indirect) |
View |
| 2019-02-04 Option Award |
2019-02-06 5:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
1,818,475 | $0 | 8,837,349 (Indirect) |
View |
| 2018-09-20 Option Award |
2018-09-24 08:59 am |
N/A 2028-09-19 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Patel Sanj K CEO, Chairman |
125,000 | $30.93 | 125,000 (Direct) |
View |
| 2018-09-20 Option Award |
2018-09-24 08:59 am |
N/A 2028-09-19 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Paolini John F. SVP & Chief Medical Officer |
45,000 | $30.93 | 45,000 (Direct) |
View |
| 2018-09-20 Option Award |
2018-09-24 08:58 am |
N/A 2028-09-19 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Mahoney Stephen F. COO |
50,000 | $30.93 | 50,000 (Direct) |
View |
| 2018-09-20 Option Award |
2018-09-24 08:58 am |
N/A 2028-09-19 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Heberlig Chris CFO |
45,000 | $30.93 | 45,000 (Direct) |
View |
| 2018-09-20 Option Award |
2018-09-24 08:57 am |
N/A 2028-09-19 |
Kiniksa Pharmaceuticals Ltd. | KNSA | Beetham Thomas W. EVP & Chief Legal Officer |
45,000 | $30.93 | 45,000 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-31 4:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Flynn James E Deerfield Mgmt L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Special Situations Fund L.P. DEERFIELD PARTNERS L.P. 10% Owner |
383,538 | $0 | 843,352 (Indirect) |
View |
| 2018-05-29 Conversion |
2018-05-31 4:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Flynn James E Deerfield Mgmt L.P. DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) Deerfield Special Situations Fund L.P. DEERFIELD PARTNERS L.P. 10% Owner |
383,538 | $0 | 843,352 (Indirect) |
View |
| 2018-05-29 Conversion |
2018-05-31 4:13 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Cormorant Asset Management LP Chen Bihua Cormorant Global Healthcare GP LLC Cormorant Global Healthcare Master Fund LP 10% Owner |
830,999 | $0 | 900,443 (Indirect) |
View |
| 2018-05-29 Conversion |
2018-05-31 4:13 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Cormorant Asset Management LP Chen Bihua Cormorant Global Healthcare GP LLC Cormorant Global Healthcare Master Fund LP 10% Owner |
830,999 | $0 | 900,443 (Direct) |
View |
| 2018-02-09 Purchase |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
420,897 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Purchase |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
3,734,103 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
420,897 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
420,897 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
3,734,103 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
3,734,103 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
313,621 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
313,621 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
3,284,771 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
3,284,771 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
1,399,516 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
1,399,516 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
14,658,102 | $0 | 14,658,102 (Indirect) |
View |
| 2018-02-09 Conversion |
2018-05-31 4:10 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BAKER BROS. ADVISORS LP 667 L.P. Baker Bros. Advisors (GP) LLC Baker Brothers Life Sciences LP BAKER FELIX BAKER JULIAN Director, 10% Owner |
14,658,102 | $0 | 14,658,102 (Indirect) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Patel Sanj K CEO, Chairman |
135,889 | $0 | 1,526,160 (Direct) |
View |
| 2018-05-29 Purchase |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Patel Sanj K CEO, Chairman |
63,922 | $15.64 | 1,526,160 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Patel Sanj K CEO, Chairman |
428,203 | $0 | 1,526,160 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Patel Sanj K CEO, Chairman |
71,967 | $0 | 1,526,160 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Patel Sanj K CEO, Chairman |
63,922 | $0 | 1,526,160 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Patel Sanj K CEO, Chairman |
428,203 | $0 | 1,526,160 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Beetham Thomas W. Chief Legal Officer |
6,392 | $0 | 414,157 (Direct) |
View |
| 2018-05-29 Purchase |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Beetham Thomas W. Chief Legal Officer |
6,392 | $15.64 | 414,157 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Beetham Thomas W. Chief Legal Officer |
48,172 | $0 | 414,157 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Beetham Thomas W. Chief Legal Officer |
6,392 | $0 | 414,157 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:20 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Beetham Thomas W. Chief Legal Officer |
48,172 | $0 | 414,157 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Malley Thomas Director |
71,967 | $0 | 71,967 (Indirect) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Malley Thomas Director |
71,967 | $0 | 71,967 (Indirect) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BOESS CARSTEN 10% Owner |
6,392 | $0 | 473,035 (Direct) |
View |
| 2018-05-29 Purchase |
2018-05-29 7:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BOESS CARSTEN 10% Owner |
6,392 | $15.64 | 473,035 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BOESS CARSTEN 10% Owner |
107,050 | $0 | 473,035 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BOESS CARSTEN 10% Owner |
6,392 | $0 | 473,035 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:19 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | BOESS CARSTEN 10% Owner |
107,050 | $0 | 473,035 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Mahoney Stephen F. COO |
6,392 | $0 | 656,027 (Direct) |
View |
| 2018-05-29 Purchase |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Mahoney Stephen F. COO |
6,392 | $15.64 | 656,027 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Mahoney Stephen F. COO |
107,050 | $0 | 656,027 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Mahoney Stephen F. COO |
6,392 | $0 | 656,027 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Mahoney Stephen F. COO |
107,050 | $0 | 656,027 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Heberlig Chris CFO |
6,392 | $0 | 440,920 (Direct) |
View |
| 2018-05-29 Purchase |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Heberlig Chris CFO |
6,392 | $15.64 | 440,920 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Heberlig Chris CFO |
74,935 | $0 | 440,920 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Heberlig Chris CFO |
6,392 | $0 | 440,920 (Direct) |
View |
| 2018-05-29 Conversion |
2018-05-29 7:18 pm |
N/A N/A |
Kiniksa Pharmaceuticals Ltd. | KNSA | Heberlig Chris CFO |
74,935 | $0 | 440,920 (Direct) |
View |
|
© 2005-2019 SecForm4.Com All rights reserved. Archives: 2019 2018 2017 2016 2015 2014 ... Thu, 18 Jul 2019 18:40:18 -0500 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |